drug
atrasentan hydrochloride
Marketedupdated 5mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
all catalysts(2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 22, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Mar 25, 2043method-of-use (U-3980)US 12582631
- Feb 23, 2041method-of-use (U-3980)US 12521369
- Dec 16, 2040method-of-use (U-3980)US 11491137
- Dec 16, 2040method-of-use (U-3980)US 11998526
- Dec 16, 2040method-of-use (U-3980)US 12121509
- Dec 16, 2040method-of-use (U-3980)US 12370174
- Jul 7, 2034formulationUS 10016393
- Jul 7, 2034formulationUS 9364458
- Feb 18, 2032method-of-use (U-3980)US 11874283
- Aug 22, 2028method-of-use (U-3980)US 86238191.9y
FDA exclusivities (1)
- Apr 2, 2030NCENew Chemical Entity (5y)3.5y
News(2)
- Novartis shareholder calls for board overhaul following costly deal setbacks: ReutersNovartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.fiercebiotech · 19d ago
- STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and moreEyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goalstat · 1mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that